Multi-state survival analysis in cost-effectiveness studies: the case of capecitabine versus docetaxel in metastatic breast cancer (mbc) for a private payer in Brazil

被引：0
|
作者：
Santos, E. A. [1 ]
Marques, R. M. [2 ]
机构：
[1] Roche Brazil, Sao Paulo, Brazil
[2] Hosp Sirio Libanes, Sao Paulo, Brazil
来源：
VALUE IN HEALTH | 2007年 / 10卷 / 06期
关键词：
D O I：
10.1016/S1098-3015(10)65219-9
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A341 / A341
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness of capecitabine in combination with docetaxel versus docetaxel monotherapy in patients with advanced and/or metastatic breast cancer in France
    Lilliu, H
    Le Pen, C
    Priol, G
    Perez-Niddam, K
    Aultman, R
    Garrison, L
    VALUE IN HEALTH, 2003, 6 (06) : 626 - 626
  • [2] Population based cost-effectiveness analysis of combination capecitabine and docetaxel (DC) versus single agent docetaxel (D) in the treatment of metastatic breast cancer (MBC) following an anthracycline regimen
    Taylor, SM
    Barnett, J
    Chia, S
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S67 - S67
  • [3] Cost-effectiveness analysis of capecitabine in combination with docetaxel in comparison to docetaxel monotherapy in advanced or metastatic breast cancer in France
    Priol, G
    Maurel, F
    Le Pen, C
    BULLETIN DU CANCER, 2005, 92 (09) : 809 - 816
  • [4] Cost-effectiveness analysis of utidelone plus capecitabine for metastatic breast cancer in China
    Liao, Mengting
    Jiang, Qin
    Hu, Huabin
    Han, Jiaqi
    She, Longjiang
    Yao, Linli
    Ding, Dong
    Huang, Jin
    JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (06) : 584 - 592
  • [5] Survival and cost-effectiveness of docetaxel (D) and paclitaxel (P) in patients with metastatic breast cancer (MBC): A population-based evaluation.
    Vu, T. T.
    Ellard, S.
    Olivotto, I.
    Taylor, S. C.
    De Lemos, M. L.
    Speers, C.
    Kuik, K.
    Hu, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 329S - 329S
  • [6] COST-EFFECTIVENESS ANALYSIS OF LAPATINIB ASSOCIATED TO CAPECITABINE VERSUS CAPECITABINE ALONE AND OF TRASTUZUMAB ASSOCIATED TO CAPECITABINE VERSUS CAPECITABINE ALONE IN THE TREATMENT OF METASTATIC BREAST CANCER UNDER THE BRAZILIAN PRIVATE HEALTH CARE SYSTEM PERSPECTIVE
    Teich, V
    Passos, R. B. F.
    Teich, N.
    Canella, M.
    VALUE IN HEALTH, 2009, 12 (07) : A497 - A497
  • [7] COST-EFFECTIVENESS ANALYSIS OF TRASTUZUMAB plus DOCETAXEL VERSUS DOCETAXEL ALONE IN THE TREATMENT OF HER2+METASTATIC BREAST CANCER
    Athanasakis, K.
    Golna, C.
    Kyriopoulos, J.
    VALUE IN HEALTH, 2011, 14 (07) : A449 - A449
  • [8] Adapting a population cost-effectiveness model for capecitabine-docetaxel combination therapy for metastatic breast cancer.
    Verma, S
    Ilersich, AL
    BREAST CANCER RESEARCH AND TREATMENT, 2001, 69 (03) : 253 - 253
  • [9] A comparison of lapatinib plus capecitabine versus capecitabine for quality-adjusted survival in metastatic breast cancer (MBC): A QTWiST analysis
    Sherrill, B.
    Allshouse, A.
    Amonkar, M. M.
    Walker, M. D.
    Stein, S. H.
    EJC SUPPLEMENTS, 2007, 5 (04): : 227 - 227
  • [10] Cost-effectiveness Analysis in R Using a Multi-state Modeling Survival Analysis Framework: A Tutorial
    Williams, Claire
    Lewsey, James D.
    Briggs, Andrew H.
    Mackay, Daniel F.
    MEDICAL DECISION MAKING, 2017, 37 (04) : 340 - 352
12345